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Introduction and Aims: Vascular calcification is widely regarded as an active
cell-mediated phenomenon, triggered by chronic exposure of the vasculature to
inappropriate environmental cues like high phosphate concentrations, which drive the
transdifferentiation of vascular cells toward a mineralising phenotype. Recent work has
focused on the involvement of phosphate-induced mineral nanocrystals as direct
mediators of this process, but their role in the pathogenesis of arterial calcification
remains unclear.
Methods: Here we investigated the effect of native serum-derived calciprotein particles
(CPP), on mineral deposition, calcification inhibitory pathways and changes in
mineralisation- and inflammation-related gene expression in primary human aortic
vascular smooth muscle cells (HAVSMC) in vitro. We assessed the dependency of
changes in HAVSMC mineralisation on phenotypic reprograming directed by
Runt-related factor-2 (Runx2), a key osteogenic transcription factor, and defined the
temporal inter-relationship of spontaneous CPP formation, HAVSMC mineralisation
and phenotypic adaptations in response to high-phosphate culture. Since the ripening
of CPP from small amorphous calcium phosphate-containing particles (CPP-I) to
larger particles with a crystalline mineral core (CPP-II) appears to be a critical
determinant of biological effect and predictive of patient outcome, we also investigated
the effect of CPP maturation on these mineralisation phenomena.
Results: Exposure of HAVSMC to CPP-II, but not CPP-I, accelerated the passive
mineralisation of HAVSMC in normophosphataemic media (1 mmol/L), but only
induced limited expression of bone-related markers (osteopontin, matrix Gla protein)
and without changes in Runx2 transcriptional activation or the expression of
downstream effectors (alkaline phosphatase). Although culture of HAVSMC in
high-phosphate containing media (2.5 mmol/L) resulted in modest Runx2
transcriptional activation, these cellular changes were preceded by de novo CPP-I
formation, ripening to CPP-II and passive deposition of mineral on the cell monolayer.
Critically, while inhibition of CPP formation with pyrophosphate or phosphonoformic
acid (crystal poisons) completely abrogated mineralisation in HAVSMC, it had
minimal effect on high-phosphate induced Runx2 up-regulation. Moreover, stable
knockdown of Runx2 in HAVSMC using a shRNA lentiviral expression system had no
effect on either CPP or high-phosphate induced mineral deposition.
Conclusions: High-phosphate-induced mineralisation of HAVSMC in vitro is strongly
dependent on CPP formation, whereas Runx2 upregulation may not be an absolute
prerequisite but may in contrast be induced by phosphate independent of CPP
generation. Therapies aimed at minimising the transformation of CPP-I to CPP-II, or
enhancing particle clearance may help limit CPP-related vascular calcification and
cardiovascular sequelae.
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